143 related articles for article (PubMed ID: 26586938)
1. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered.
Ortiz A; Sanchez-Niño MD
Drug Des Devel Ther; 2015; 9():5873-4. PubMed ID: 26586938
[No Abstract] [Full Text] [Related]
2. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.
Goláň L; Goker-Alpan O; Holida M; Kantola I; Klopotowski M; Kuusisto J; Linhart A; Musial J; Nicholls K; Gonzalez-Rodriguez D; Sharma R; Vujkovac B; Chang P; Wijatyk A
Drug Des Devel Ther; 2015; 9():3435-44. PubMed ID: 26185417
[TBL] [Abstract][Full Text] [Related]
3. Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
Pisani A; Riccio E; Sabbatini M
Genet Med; 2015 Jan; 17(1):21-3. PubMed ID: 25010055
[No Abstract] [Full Text] [Related]
4. Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America.
Ripeau D; Amartino H; Cedrolla M; Urtiaga L; Urdaneta B; Cano M; Valdez R; Antongiovanni N; Masllorens F
Medicina (B Aires); 2017; 77(3):173-179. PubMed ID: 28643672
[TBL] [Abstract][Full Text] [Related]
5. Disease progress in patients with Morbus Fabry after switching from agalsidase beta to agalsidase alpha.
Reidt S; Namdar M; Serra A; Krayenbühl PA; Gruner C; Keller DI; Lüscher TF; Schmied C
Intern Med J; 2014 Feb; 44(2):205-7. PubMed ID: 24528819
[No Abstract] [Full Text] [Related]
6. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease.
Hughes DA; Deegan PB; Milligan A; Wright N; Butler LH; Jacobs A; Mehta AB
Mol Genet Metab; 2013 Jul; 109(3):269-75. PubMed ID: 23702393
[TBL] [Abstract][Full Text] [Related]
8. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
Senocak Tasci E; Bicik Z
Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
[TBL] [Abstract][Full Text] [Related]
9. Authors’ reply.
Goláň L; Chang P
Drug Des Devel Ther; 2015; 9():5875. PubMed ID: 26918251
[No Abstract] [Full Text] [Related]
10. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
Goker-Alpan O; Longo N; McDonald M; Shankar SP; Schiffmann R; Chang P; Shen Y; Pano A
Drug Des Devel Ther; 2016; 10():1771-81. PubMed ID: 27307708
[TBL] [Abstract][Full Text] [Related]
11. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
[TBL] [Abstract][Full Text] [Related]
12. [The switch of enzyme therapy in Fabry disease].
Riccio E; Pisani A
G Ital Nefrol; 2014; 31(4):. PubMed ID: 25098458
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of agalsidase beta in Japanese patients with Fabry disease: aggregate data from two post-authorization safety studies.
Tsurumi M; Suzuki S; Hokugo J; Ueda K
Expert Opin Drug Saf; 2021 May; 20(5):589-601. PubMed ID: 33599146
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
15. Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina.
Kisinovsky I; Cáceres G; Coronel C; Reisin R
Medicina (B Aires); 2013; 73(1):31-4. PubMed ID: 23335703
[TBL] [Abstract][Full Text] [Related]
16. [Current status and future prospect of enzyme replacement therapy for Fabry disease].
Ohashi T
Rinsho Shinkeigaku; 2019 Jun; 59(6):335-338. PubMed ID: 31142708
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of Fabry disease: Successes, failures, and expectations].
Lidove O; Barbey F; Joly D
Nephrol Ther; 2016 Apr; 12 Suppl 1():S105-13. PubMed ID: 26968478
[TBL] [Abstract][Full Text] [Related]
18. Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis.
Hughes D; Linhart A; Gurevich A; Kalampoki V; Jazukeviciene D; Feriozzi S;
Drug Des Devel Ther; 2021; 15():3561-3572. PubMed ID: 34429585
[TBL] [Abstract][Full Text] [Related]
19. Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?
Fauchais AL; Prey S; Ouatara B; Vidal E; Sparsa A
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):737-8. PubMed ID: 19925601
[No Abstract] [Full Text] [Related]
20. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.
Schiffmann R; Ries M; Timmons M; Flaherty JT; Brady RO
Nephrol Dial Transplant; 2006 Feb; 21(2):345-54. PubMed ID: 16204287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
